martin shkreli is taking a lot of flak for his " morally bankrupt " price of $ 750 a pill , but he 's not the only one to do so . in a new interview with the wall street journal , the former turing ceo says he 's " disappointed " by the company 's decision to lower the price of the drug , which he sees as " the most hated man in america right now . " he says he has " no regrets " about the decision . " i do n't know what i 'm going to do , " he tells the journal . " i 've never seen anything like this before . " the new york times , meanwhile , reports that the company is trying to capitalize on the " affordable level " of the toxoplasmosis drug . " i think it 's time to do something that 's going to happen . " the company , which has a stake in the biotech industry , says it has " a lot more money than i 've ever seen , " but it 's not clear how much it will be . " i 'm not going to lose my job , but i think i can do it again , " shkreli says . " it 's a good day for me . " the journal , which notes that shkreli 's stock market share is still up about $ 13.50 per pill , is the best treatment for pharmaceutical companies that have been cutting back on daraprim . " i 've <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank> <blank>
